ALK and non-small cell lung carcinoma: Furthermore, in the randomized, open-label, phase III clinical trial ALESIA, which enrolled only Asian patients with ALK-positive NSCLC between August 2016 and May 2017, alectinib at a dose of 600 mg orally twice daily was compared to crizotinib as a first-line treatment.